> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Par Recalls 1 Lot of Mycophenolate Mofetil
- URL: https://www.fdaweb.com/par-recalls-1-lot-of-mycophenolate-mofetil/
- Published: 2019-05-06T12:00:00.000Z
- Updated: 2026-09-15T01:24:42.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5144036

Par Pharmaceutical has recalled one lot of mycophenolate mofetil for injection after one product vial was observed containing a glass fragment after reconstitution. “The administration of a glass particulate, if present in an intravenous drug, may result in local irritation or swelling in response to the foreign material,” a [recall notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/par-pharmaceutical-inc-issues-voluntary-nationwide-recall-one-lot-mycophenolate-mofetil-injection?utm%5Fcampaign=FDA%20MedWatch%20-Mycophenolate%20Mofetil%20for%20Injection&utm%5Fmedium=email&utm%5Fsource=Eloqua) says. “More serious potential outcomes would include blockage and clotting in blood vessels, which may be life-threatening.” Mycophenolate mofetil is indicated for preventing organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.